E-drug: Anti retrovirals (cont)
---------------------------------------------
Now I am really confused. Messages about generic AZT/zidovudine from Leo
Offerhaus and Richard Laing on the one side, and from David Scondras and
Khalil Elouardighi on the other side, conflict so much that I don't know
any more what to advise people. This week I have to talk to some British
members of parliament about TRIPS, compulsory licensing and access to
treatment for HIV in developing countries - what should I tell them?
This is not an academic debate, it is about a tragic reality for 95
percent of the people who live with HIV/|AIDS. If planning and advocacy
for the future is to be successful or even possible, the essential drugs
experts and the HIV experts should be pooling their knowledge and
evidence as a priority, and making it readily available via both the
essential drugs AND the HIV networks. Together, we need to be able to
work out some sustainable methods of improving access to drugs. We need
hard facts and evidence to do this, not rhetoric.
IS there anyone out there who is scientifically expert enough in drug
formulation and production AND who understands the effects of the AIDs
epidemic, who can shed some light on the situation? Please help.
Carolyn Green Consulting Pharmacist
3 Leslie Grove Psychotherapist
Croydon
Surrey CR0 6TJ
UK
tel: +44(0) 20 8686 3831
e-mail: greencm@dial.pipex.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.